Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

J Thorac Dis：吴一龙等研究认为应对疑似肺癌患者活检原则进行权衡考量

2013-07-09 ecoliDH5 DXY

吴一龙广东省人民医院肺癌
关注

PET/CT扫描结果 占位部针刺活检及肌内结节切除样本 支气管镜及右上肺叶切除样本 在2013年6月期的《胸科疾病杂志》(Journalof Thoracic Disease)上，发表了我国广东省人民医院吴一龙教授等人的一篇文章。该文对活检原则进行了重新审视。在临床实践中，可通过多种手段获取到疑似肺癌患者的活检样本。既往文献认为，为达到诊断目的


PET/CT扫描结果


占位部针刺活检及肌内结节切除样本


支气管镜及右上肺叶切除样本

在2013年6月期的《胸科疾病杂志》(Journalof Thoracic Disease)上，发表了我国广东省人民医院吴一龙教授等人的一篇文章。该文对活检原则进行了重新审视。在临床实践中，可通过多种手段获取到疑似肺癌患者的活检样本。既往文献认为，为达到诊断目的，应优先考虑安全性最高、伤害最小且费用最低的活检方式。随着对分子特征的了解日益深入以及靶向治疗的发展，原有肿瘤活检的概念受到了冲击。因此为适应临床研究的发展，应对活检的不同原则进行重新考量。

广东省人民医院曾收治过一例因血痰住院的53岁男性患者，该患者有10年粉尘曝露史。PET/CT扫描结果表明，患者右上肺叶部存在一处3.2厘米占位，该占位处18F-FDG摄取值升高，并且患者纵膈多站点或双侧肺门淋巴结病变部位以及左股大肌肌内结节代谢活跃。

经按顺序对该患者进行了肺占位部穿刺活检、肌内结节切除、支气管镜检及右上肺叶切除后，最终诊断结果认为是全身性脂质沉积。

作者最终认为，应按照临床控制、组织的获取情况、伤害性以及效率和开支的优先顺序原则，针对疑似肺癌患者进行活检。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2011833, encodeId=37b8201183339, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jul 15 16:27:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056961, encodeId=224720569617e, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17404, encryptionId=a19b1e4042f, topicName=THORAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Sat Mar 08 17:27:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990519, encodeId=0d01199051948, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sat Oct 19 02:27:00 CST 2013, time=2013-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277940, encodeId=ac4312e794023, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu Jul 11 01:27:00 CST 2013, time=2013-07-11, status=1, ipAttribution=)]
    2013-07-15 cmj8wellington

    #Dis#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2011833, encodeId=37b8201183339, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jul 15 16:27:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056961, encodeId=224720569617e, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17404, encryptionId=a19b1e4042f, topicName=THORAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Sat Mar 08 17:27:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990519, encodeId=0d01199051948, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sat Oct 19 02:27:00 CST 2013, time=2013-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277940, encodeId=ac4312e794023, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu Jul 11 01:27:00 CST 2013, time=2013-07-11, status=1, ipAttribution=)]
    2014-03-08 yyj062

    #THORAC#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2011833, encodeId=37b8201183339, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jul 15 16:27:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056961, encodeId=224720569617e, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17404, encryptionId=a19b1e4042f, topicName=THORAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Sat Mar 08 17:27:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990519, encodeId=0d01199051948, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sat Oct 19 02:27:00 CST 2013, time=2013-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277940, encodeId=ac4312e794023, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu Jul 11 01:27:00 CST 2013, time=2013-07-11, status=1, ipAttribution=)]
    2013-10-19 gds2009

    #肺癌患者#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2011833, encodeId=37b8201183339, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jul 15 16:27:00 CST 2013, time=2013-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056961, encodeId=224720569617e, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17404, encryptionId=a19b1e4042f, topicName=THORAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Sat Mar 08 17:27:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990519, encodeId=0d01199051948, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sat Oct 19 02:27:00 CST 2013, time=2013-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277940, encodeId=ac4312e794023, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu Jul 11 01:27:00 CST 2013, time=2013-07-11, status=1, ipAttribution=)]
    2013-07-11 smlt2008

    #活检#

    0

相关资讯

吴一龙：2011年肺癌研究进展回顾

图基于致癌驱动基因的肿瘤治疗模式 　　2011年末，世界顶尖癌症研究杂志《癌细胞》（Cancer Cell）出版增刊《关注中国》（Spotlights on China），着力介绍中国的癌症研究机构、学术组织以及癌症研究亮点。在特别辟出介绍中国肺癌临床研究的章节中，文章作者认为，中国胸部肿瘤协作组（CTONG）领导的基于中国人基因特点的系列靶向治疗研究，使中国在肺癌

Baidu
map
Baidu
map
Baidu
map